Journal article
Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer
Abstract
BACKGROUND: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC.
OBJECTIVE: To validate Xpert characteristics in patients previously diagnosed with …
Authors
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK
Journal
European Urology, Vol. 75, No. 5, pp. 853–860
Publisher
Elsevier
Publication Date
May 2019
DOI
10.1016/j.eururo.2018.11.055
ISSN
0302-2838
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAnnexinsBiopsyCorticotropin-Releasing HormoneCystoscopyFemaleHumansInsulin-Like Growth Factor IIMaleMiddle AgedNeoplasm Recurrence, LocalPopulation SurveillancePredictive Value of TestsProspective StudiesProto-Oncogene Proteins c-ablRNA, MessengerUrinalysisUrinary BladderUrinary Bladder NeoplasmsUroplakin IbYoung Adult